Caty Reid

Caty is a seasoned leader with hands-on experience launching novel technologies in complex markets. Caty’s career has been characterized by her unique blend of consumer and healthcare marketing expertise, making her an invaluable asset in bringing Akili’s digital therapeutics to those challenged with cognitive impairments. 

Caty has previously held leadership positions at PathAI and Foundation Medicine, two cutting-edge diagnostic companies with distinct technologies. At PathAI, she launched the company’s first digital pathology platform for clinical diagnosis with 510(k) clearance from the FDA. At Foundation Medicine, she launched the company’s first FDA-approved liquid biopsy diagnostic to make comprehensive genomic profiling accessible to more patients with cancer. Caty also spent a decade of her career agency-side, partnering with clients on launch strategies that spanned industries, including launching the first-ever running product for Clif Bar & Company and a new internal banking system for HSBC. Through her strategic vision and unwavering commitment to improving lives, she has consistently excelled in navigating the complexities of the healthcare landscape, effectively bridging the gap between innovative technologies and the needs of consumers. Notably, Caty’s work has driven quantifiable results for various organizations, making a significant impact in the healthcare and technology sectors.